On February 1, 2016, the Centers for Medicare and Medicaid Services (CMS) published 42 CFR, Part 447: Medicaid Program Covered Outpatient Drugs with final comments (CMS-2345-FC). This rule addresses regulations that pertain to reimbursement for covered outpatient drugs in the Medicaid program. The document is available online at http://federalregister.gov/a/2016-01274.
On March 8, 2016, the Division of Medicaid (DOM) held an initial Pharmacy Stakeholder meeting for the purpose of reviewing CMS-2345-FC.
The invited organizations included:
- Independent Nursing Home Association (INHA)
- Magnolia Health
- MS Association of Community Mental Health Centers (MACMHC)
- MS Hospital Association (MHA)
- MS Independent Pharmacies Association (MIPA)
- MS Pharmacists Association (MPhA)
- MS Primary Health Care Association (MHCA)
- MS Society of Health-Systems Pharmacists (MSHP)
- MS State Medical Association (MSMA)
- National Association of Chain Drug Stores (NACDS)
- United Healthcare
- Pharmacy Stakeholder meeting presentation – March 2016
On May 19, 2016, Division of Medicaid (DOM) held a Pharmacy Stakeholder Meeting to provide viable reimbursement options to pharmacy stakeholders.
- Pharmacy Stakeholder meeting presentation – May 2016
On June 28, 2016, Division of Medicaid (DOM) held a Pharmacy Stakeholder Meeting to address questions and/or comments from pharmacy stakeholders regarding viable reimbursement options for covered outpatient drugs in the Medicaid program.
- Pharmacy Stakeholder meeting presentation – June 2016
On August 2, 2016, Division of Medicaid (DOM) held a Pharmacy Stakeholder Meeting to begin discussions regarding reimbursement options for specialty drugs in the Medicaid program.
- Pharmacy Stakeholder meeting presentation – August 2016
On October 12, 2016, the Division of Medicaid (DOM) held a Pharmacy Stakeholder Meeting to gather feedback on reimbursement options for specialty drugs and hemophilia factor products.
- Pharmacy Stakeholder meeting – Specialty Drugs presentation – October 2016
- Pharmacy Stakeholder meeting – Hemophilia Factor presentation – October 2016
